Genome-wide transcriptome profiling of human trabecular meshwork cells treated with TGF-β2

Breedge Callaghan1,6, Karen Lester1,2,6, Brian Lane2,3, Xiaochen Fan2, Katarzyna Goljanek-Whysall2,4, David A. Simpson5, Carl Sheridan2 & Colin E. Willoughby1,2*

Glaucoma is a complex neurodegenerative disease resulting in progressive optic neuropathy and is a leading cause of irreversible blindness worldwide. Primary open angle glaucoma (POAG) is the predominant form affecting 65.5 million people globally. Despite the prevalence of POAG and the identification of over 120 glaucoma related genetic loci, the underlying molecular mechanisms are still poorly understood. The transforming growth factor beta (TGF-β) signalling pathway is implicated in the molecular pathology of POAG. To gain a better understanding of the role TGF-β2 plays in the glaucomatous changes to the molecular pathology in the trabecular meshwork, we employed RNA-Seq to delineate the TGF-β2 induced changes in the transcriptome of normal primary human trabecular meshwork cells (HTM). We identified a significant number of differentially expressed genes and associated pathways that contribute to the pathogenesis of POAG. The differentially expressed genes were predominantly enriched in ECM regulation, TGF-β signalling, proliferation/apoptosis, inflammation/wound healing, MAPK signalling, oxidative stress and RHO signalling. Canonical pathway analysis confirmed the enrichment of RhoA signalling, inflammatory-related processes, ECM and cytoskeletal organisation in HTM cells in response to TGF-β2. We also identified novel genes and pathways that were affected after TGF-β2 treatment in the HTM, suggesting additional pathways are activated, including Nrf2, PI3K-Akt, MAPK and HIPPO signalling pathways. The identification and characterisation of TGF-β2 dependent differentially expressed genes and pathways in HTM cells is essential to understand the patho-physiology of glaucoma and to develop new therapeutic agents.

Glaucoma is a neurodegenerative disease resulting in progressive optic neuropathy and is a leading cause of irreversible blindness worldwide. Primary open angle glaucoma (POAG) is the predominant form accounting for approximately two-thirds of glaucoma patients affecting 65.5 million people globally. The pathogenesis of POAG is multi-factorial and complex. Elevation of intra-ocular pressure (IOP) has been identified as a significant risk factor for POAG. Multiple international randomised controlled trials have demonstrated that medically or surgically lowering IOP reduces glaucoma progression. Changes to intra-ocular pressure are generated by resistance to fluid outflow in the trabecular meshwork (TM). Outflow resistance is higher in POAG patients because of cellular and molecular changes in the TM resulting in reduced outflow facility. Despite the prevalence of POAG and the identification of over 120 glaucoma related genomic loci, the molecular mechanisms of POAG are still poorly understood. However, bioinformatic analyses of glaucoma related genes have repeatedly identified the transforming growth factor beta (TGF-β) signalling pathway in the molecular pathology of POAG.

Physiologically, TGF-β2 is produced by the ciliary epithelium and lens epithelium. Multiple studies have identified elevated concentrations of TGF-β2 in the aqueous humour of POAG patients however the
sequences and they are not without their limitations. However, RNA-Seq technology offers significant benefits over previous microarray technologies with improved dynamic range, depending on sequence depth, detection of transcript isoforms (splicing) and novel transcripts.

Therefore, the aim of this study was to employ RNA-Seq to investigate genome-wide alterations in the transcriptome of normal human donor TM cells stimulated with TGF-β2 and investigate possible pathophysiological mechanisms driving POAG.

Materials and methods
Sample collection, preparation, and tissue culture. Cadaveric eyes (n = 5) were provided by the Liverpool Research Eye Bank and approved by the local ethics review board (RETH000833) handled in accordance with the tenets of the Declaration of Helsinki. Eyes were obtained from the Royal Liverpool University Hospital Mortuary and medical history was unknown. Donor eyes were excluded if the maximum post-mortem time exceeded 48 h or there was a history of glaucoma or ocular surgery (Supplemental Fig. 1). TM cells were isolated using the blunt dissection method as reported previously. Cells were maintained in Dulbecco’s Modified Eagle Media (DMEM)-low glucose (Sigma, UK) supplemented with 10% fetal calf serum (Bio Sera, UK), 2 mM l-glutamine (Sigma, UK), Pen/Step (Sigma, UK), and 2.5 µg/mL Fungizone (amphotericin B, Sigma, UK). Samples were incubated at 37 °C (5% CO2 and 95% humidity). TM characterisation was carried out as previously described and demonstrated upregulated myocilin protein expression in response to dexamethasone treatment.

TGF-β2 stimulation. Human TM cells between passages 5 and 7 were grown to 80% confluence and growth arrested using serum free medium prior to stimulation. Cells were stimulated with recombinant human TGF-β2 (R&D Systems, UK) at a concentration of 5 ng/mL for 24 h. Vehicle control cells were stimulated with equal volumes of 4 mM HCl and 0.1% BSA solution (Sigma, UK). The viability of TM cells treated with TGF-β2 was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (MTT, Sigma-Aldrich, USA) (Supplemental Fig. 1C). 24 h post TGF-β2 treatment, 10uM of MTT solution was added to each well and incubated for 3 h. After incubation, the media was removed and the formazan crystals were dissolved in 100 µl of DMSO. The optical densities (OD) of the dissolved formazan crystals was read on a plate reader at 570 nm (Omega FluroStar; US). The quantification of cell viability was obtained by comparing the optical density of the treated and untreated samples. The relative cell viability was calculated for each tissue as Arbitral Unit (AU), extrapolated by Optical Density (OD) of the samples.

RNA-seq of TGF-β2 stimulated TM cells. Total RNA from human cultured TM cells was isolated using the Qiagen Universal All Prep (Qiagen, UK) kit as per manufacturer’s specifications. Total RNA was quantified on the Nanodrop-1000 (Thermofisher, UK), and quality was determined by the Bioanalyser 2100 (Agilent, UK). All RNA sequencing experiments were conducted at Exiqon Services, Denmark. Two groups of mRNA libraries were prepared: a group of 5 control human TM samples (Donor Control) and a group of 5 treated TM samples (Donor Treated). After extracting the total RNA, mRNA was enriched using the oligoT bead system and the isolated mRNA was enzymatically fragmented. First and second strand synthesis were performed, and the double stranded cDNA was purified (AMPure XP, Beckman Coulter, Denmark). The cDNA was end repaired, 3’ adenylated and Illumina sequencing adaptors ligated onto the fragments ends. Following this the mRNA
stranded libraries were pre-amplified with PCR and purified (AMPure XP). Library size distribution was validated, and quality was inspected on a Bioanalyzer high sensitivity DNA chip (Agilent Technologies, UK). High quality libraries were quantified using q-PCR, the concentration normalised, and the samples pooled according to the project specification (number of reads). The library pools were re-quantified with q-PCR and optimal concentration of the library pool was used to generate the clusters on the surface of a flowcell before sequencing on a Nextseq 500 instrument using a High Output sequencing kit (51 cycles) according to the manufacturer instructions (Illumina Inc., USA).

**RNA-Seq data analysis.** Following sequencing, intensity correction and base calling (into BCL files), FASTQ files were generated using appropriate bcl2fastq software (Illumina Inc.) which includes quality scoring of each individual base in a read. Data was separated for paired end reads to determine whether the second read significantly differs from the first in terms of overall quality. Data analysis was performed by Exiqon (Exiqon, Denmark). The components of Exiqon NGS RNA-Seq analysis pipeline include Bowtie2 (v.2.2.2), TopHat (v.2.0.11) and Cufflinks (v.2.2.1). As we were comparing groups, Cuffdiff, normally used for unpaired samples to calculate FPKM (number of fragments per kilobase per million mapped fragments) was replaced with featureCounts. FeatureCounts was used to calculate the counts of mapped reads in specific genes when groups with paired samples were compared, and generalised linear model likelihood ratio test (glmLRT) implemented by edgeR was used to test differential expression across generalised samples using featureCounts input. Post processing of Cufflinks and Cuffdiff was performed using CummeRbund and Bioconductor software to generate visual representations of sequencing results. The raw RNA-Seq data was deposited and released in the SRA database (Study: PRJNA820984; Accessions: SAMN27032229).

**Bioinformatic analysis of biological process and pathways.** Following analysis by Exiqon (Denmark), further functional analysis was performed through Database for Annotation, Visualization and Integrated Discovery (DAVID) bioinformatic package, (available at [http://david.abcc.ncifcrf.gov](http://david.abcc.ncifcrf.gov)) and Ingenuity Pathway Analysis (IPA)31. Gene Ontology (GO) enrichment analysis was carried out to investigate relationships between the significantly expressed genes and their cellular compartment, biological processes and molecular function. Significance was calculated in DAVID using the Fisher's exact test with the Benjamini and Hochberg correction based on process enrichment score or activation z-score. Fisher's exact tests reported as a likelihood value (−log(p-value)) were performed to assess canonical pathway enrichment. Canonical pathways and upstream regulators of a single DEG supplied. The canonical pathways and upstream regulators identified in two or more core analyses in IPA were compared in comparison analyses. Comparisons were performed by hierarchical clustering based on process enrichment score or activation z-score. Fisher's exact tests reported as a likelihood value (−log(p-value)) were performed to assess canonical pathway enrichment. Canonical pathways and upstream regulators were ranked by activation z-score which is a weighted statistic that correlates measured gene expression with the expected direction of expression of the DEG list supplied. The activation score is equivalent to a zero centred normal distribution z-score therefore only scores of ± 1.96 were regarded as significant and the sign of the z-score indicates the direction of regulation of the process.

The top list of DEG were added to the STRING database to obtain the protein–protein interactions (PPI) (medium confidence 0.400) viewed on the Cytoscape software ([http://www.cytoscape.org](http://www.cytoscape.org)). Candidate genes were calculated using MCODE to create clusters followed by the ClueGo/CluePedia and KEGG-Gscape plugins, which visualises the important biological processes and pathways for clusters of genes in a functional grouped network22.

**RNA-Seq data validation.** Validation of RNA samples was performed on the same TM donor cells used in the RNA-Seq. Using Primer Design Ltd primer assays (Primer Design Ltd, UK), RT-qPCR was performed for selected significantly altered DEGs. 1ug of total RNA was reverse transcribed into cDNA using miScript II RT (Qiagen, UK) kit according to manufacturers’ specifications (Qiagen, UK). Real time analysis was performed using custom primers (Primer Design Ltd. UK) for target genes (Supplemental Table S1). RT-qPCR was performed on a LightCycler®480 real-time PCR system (Roche Diagnostics, Switzerland). All mRNA was measured at CT threshold levels and normalised with the average CT values of a reference gene; GAPDH. Values were expressed as fold increase over the corresponding values for control by the 2^−ΔΔCT method.

**Statistical analysis.** Two independent experiments were performed, and the average (± SD) results were calculated using GraphPad software (GraphPad Software, San Diego, USA). Data were expressed as the mean values ± SD and graphed using log scale. Statistical significance was analysed using a student t-test. Differences in the mean were considered statistically significant if p < 0.05.

**Results**

**Descriptive features of RNA-Seq data.** Two mRNA libraries (donor control and donor treated) were sequenced on a flow cell using NexSeq500 (Illumina Inc.). A total of 30 million 50 bp paired end reads were obtained and on average 46.3 million reads were obtained from each sample ranging from 40 to 57 million reads per sample (Supplemental Table S1). Paired-end reads were separated to determine whether the second read significantly differed from the first in overall quality. Majority of the data had a Q score greater than 30 (>99.9% correct). Mapping of sequencing data represents a useful QC step in RNA-Seq analysis pipeline as it can help
evaluate the quality of samples. The genome mapping for each sample was on average 82% and the uniformity of the mapping results suggests that the samples are comparable (Supplemental Table S2). A principal component analysis (PCA) was carried out to identify the main components of variation in the data set using the R package, prcomp (data not shown).

Differential gene expression. To determine changes in gene expression, primary TM cells were treated with 5 ng TGF-β2 and analysed using RNA-Seq. A total of 17,186 genes were differentially expressed compared to vehicle controls. The expression of 10,106 genes were found to be statistically significantly (p < 0.05) altered. All data points were graphed using a MAplot (Fig. 1A) which allowed enhanced and distinguishable expression visualisation. A selection criterion based on a statistical significance of p < 0.05 and logFC greater than 2 was applied, as visualised by the red (upregulated) and blue (downregulated) dots on the MAplot. To discriminate distinguishable expression patterns specific to the donors included in this study, the top 50 DEGs were graphed using a two-way hierarchical cluster using a Pearson Correlation distance algorithm and a complete agglomeration method with gene wise scaled and centred log transformed FPKM count data (Fig. 1B). Each donor responded to the concentration of TGF-β2 used in the study. The heat map (Fig. 1B) shows the individual donor responses to TGF-β2 and shows variability. All donors were male and aged between 57 and 65 years of age. The basis of the donor biological variability and TGF-β2 responsiveness for specific DEGs is not known and may relate to individual donor characteristics or epigenetic factors. The top 50 most up- and down-regulated genes were ranked by log FC and are shown in Tables 1 and 2, respectively.

Functional enrichment analysis of the differentially expressed genes. Canonical pathways are biological cascades that are well-defined and are responsible for the inducing a specific consequential function in a cell in response to a stimulus or biological process. In this study, we performed a canonical pathway analysis (Fig. 2A), with the use of the Ingenuity Pathway Analysis (IPA, Qiagen, UK) using the DEG, with a FDR
p-value < 0.025. A total of 254 IPA canonical pathways were significantly enriched as determined using a Fisher's Exact Benjamini Hochberg test. The top ranked canonical pathways with an enrichment score > 4 (Fisher's Exact BH adjusted p < 0.0001) were chosen for enrichment analysis.

To ascertain the potential role and function of the top DEG after TGF-β2 treatment, a GO annotation and enrichment analysis was carried out using DAVID software, on the DEG listed in Tables 1 and 2, assessing significant biological processes, cellular compartment, and molecular function (Fig. 2B). This type of analysis differs from canonical pathway analysis as it characterises functional relationships between genes that have been documented in the previous literature. Overall, a total of 75 significant processes were found to be regulated by different combinations of the top 50 most up- and down-regulated genes. The DEGs were predominantly enriched and categorised into ECM regulation (20%), TGF-β signalling (7%), SMAD signalling (7%), proliferation/apoptosis (5%), inflammation/wound healing (5%), MAPK signalling (5%), oxidative stress (3%) and RHO signalling (2%). Interestingly, common terms associated with the DEGs, between the set of DAVID and IPA analysis, include RhoA signalling, ECM, cytoskeletal organisation and inflammatory-related processes, highlighting their potential significance in TM cells in response to TGF-β2.

| Gene ID | Gene name | LogFC | p-value | FDR |
|---------|------------|-------|---------|-----|
| KANK4   | KN Motif and Ankyrin Repeat | 11.08 | 3E−95  | 9E−92|
| LINC00312 | Long Intergenic Non-Protein Coding RNA 312 | 9.65 | 1E−44  | 5E−42|
| C4orf26 | Chromosome 4 Open Reading Frame 26 | 9.39 | 7E−45  | 3E−42|
| ISLR2   | Immunoglobulin Superfamily Containing Leucine | 7.91 | 3E−80  | 6E−77|
| LDLRA4 | Low Density Lipoprotein Receptor Class A Domain Containing 4 | 7.23 | 2E−59  | 2E−56|
| RASL11B | RAS Like Family 11 Member B | 7.12 | 3E−60  | 3E−57|
| IL11    | Interleukin 11 | 7.08 | 5E−45  | 2E−42|
| LEFTY2  | Left-Right Determination Factor 2 | 6.94 | 5E−62  | 7E−59|
| EDN1    | Endothelin 1 | 6.58 | 6E−150 | 1E−145|
| LMC1D1 | LIM And Cysteine Rich Domains 1 | 6.35 | 2E−49  | 1E−46|
| S1PR5   | Sphingosine-1-Phosphate Receptor 5 | 6.14 | 3E−56  | 3E−53|
| NOX4    | NADPH Oxidase 4 | 5.87 | 2E−105 | 2E−101|
| NPPB    | Natriuretic Peptide B | 5.86 | 6E−50  | 4E−47|
| PMEP1   | Prostate Transmembrane Protein Androgen Induced 1 | 4.81 | 3E−84  | 7E−81|
| SEMA7A  | Semaphorin 7A | 4.61 | 9E−84  | 2E−80|
| CDKN2B  | Cyclin Depended Kinase Inhibitor 2B | 4.29 | 1E−92  | 4E−89|
| FSTL3   | Follistatin-Like 3 | 4.20 | 3E−99  | 1E−95|
| MYOZ1   | Myozin 1 | 4.13 | 5E−55  | 3E−52|
| INHBE   | Inhibin Beta E Subunit | 4.13 | 2E−43  | 6E−41|
| DGK1    | Diacylglycerol Kinase Iota | 4.05 | 3E−45  | 1E−42|
| FND1C   | Fibronectin Type III Domain-Containing Protein 1 | 4.02 | 7E−57  | 6E−54|
| TLL2    | Toll-like 2 | 3.92 | 3E−53  | 2E−50|
| XYL1T1  | Xylosyltransferase 1 | 3.88 | 4E−55  | 3E−52|
| COMP    | Cartilage Oligomeric Matrix Protein | 3.82 | 8E−47  | 3E−44|
| TSPAN13 | Tetraspanin 13 | 3.75 | 5E−43  | 2E−40|
| NUAK1   | NUAK Kinase Family Member 1 | 3.69 | 3E−48  | 1E−45|
| ATP10A  | ATPase Phospholipid Transporting 10A | 3.62 | 4E−66  | 6E−63|
| DAC1    | Dishevelled Binding Agonist of Beta Catenin 1 | 3.58 | 3E−58  | 3E−55|
| CDH2    | Cadherin 2 | 3.50 | 5E−44  | 2E−41|
| TEMN4   | Teneurin Transmembrane Protein 4 | 3.47 | 9E−58  | 9E−55|
| ADAMTS4 | ADAM Metalloproteinase with Thrombospondin Type 1 Motif 4 | 3.47 | 9E−55  | 5E−52|
| SPHK1   | Sphingosine Kinase 1 | 3.10 | 9E−62  | 1E−58|
| LANC12  | Lnc-C:like 2 | 3.01 | 4E−55  | 3E−52|
| PAPDC1A | Phosphatidic Acid Phosphatase Type 2 Domain-Containing Protein 1A | 2.99 | 4E−55  | 3E−52|
| ITGA11  | Integrin Subunit Alpha 11 | 2.96 | 4E−45  | 1E−42|
| ADAM19  | ADAM Metallopeptidase Domain 19 | 2.89 | 8E−49  | 4E−46|
| PDXC1   | PX Domain Containing 1 | 2.62 | 9E−49  | 5E−46|
| ENCI    | Ectodermal-Neural Cortex 1 | 2.50 | 6E−47  | 3E−44|
| DCBLD1  | Discosin, CUB, And LCLL Domain Containing 1 | 2.46 | 6E−48  | 3E−45|
| SMAD7   | SMAD Family Member 7 | 2.45 | 1E−44  | 4E−42|
| SKIL    | SKI-like Proto-Oncogene | 2.19 | 1E−47  | 7E−45|

Table 1. Top 50 up-regulated genes.
To determine potential candidate genes involved in the canonical and enriched pathways associated with the pathogenesis of POAG and TGF-β2 signalling, an analysis of the genes reoccurring within the GO and canonical pathway analyses was carried out using ClueGo/CluePedia plug-in for the Cytoscape software. A total of five biological functional changes including proliferation, apoptosis, oxidative stress, ECM regulation and adhesion/cytoskeleton in combination with four signalling pathway changes including MAPK signalling, TGF-β signalling, SMAD signalling and RHO signalling were used as the selection criteria (Fig. 3). From this analysis, we identified a role for the upregulated genes endothelin 1 (EDN1), follistatin-like protein 3 (FSTL3), KN motif and ankyrin repeat domain-containing protein 4 (KANK4), ATPase phospholipid transporting 10A (ATP10A), low density lipoprotein receptor class A domain-containing 4 (LDLRAD4), fibronectin type 3 domain-containing 1 (FNDC1), RAS-like family 11 member B (RASL11B), prostate transmembrane protein, androgen induce 1 (PMEPA1), left right determination factor 2 (LEFTY2), dishevelled binding antagonist of beta catenin 1 (DACT1), and cyclin dependent kinase inhibitor 2B (CDKN2B) were downregulated genes.

| Gene ID | Gene name | LogFC | p-value | FDR |
|---------|-----------|-------|---------|-----|
| ADH1B   | Alcohol Dehydrogenase 1B | −7.66 | 3E−102 | 2E−98 |
| STEAP4  | STEAP Family Member 4 | −5.53 | 1E−30 | 2E−28 |
| OSR2    | Odd-Skipped Related Transcription Factor 2 | −5.37 | 4E−67 | 7E−64 |
| APOL3   | Apolipoprotein L3 | −4.35 | 5E−46 | 2E−43 |
| AKR1B10 | Aldo-Keto Reductase Family 1 Member B10 | −4.24 | 2E−51 | 1E−48 |
| SLC2A12 | Solute Carrier Family 2A Member 12 | −4.16 | 1E−31 | 2E−29 |
| IFIT2   | Interferon Induced Protein With Tetratricopeptide Repeats 2 | −3.84 | 3E−38 | 8E−36 |
| AKR1C1  | Aldo-Keto Reductase Family 1 Member C1 | −3.67 | 3E−49 | 2E−46 |
| TMECI10 | Transmembrane Protein 40 | −3.65 | 8E−34 | 1E−31 |
| PSMB9   | Proteosome Subunit Beta 9 | −3.64 | 2E−37 | 4E−35 |
| COL2A1A | Collagen Type XXI Alpha 1 Chain | −3.62 | 5E−39 | 1E−36 |
| SLC40A1 | Solute Carrier Family 40 Member 1 | −3.59 | 3E−48 | 2E−45 |
| IFIT3   | Interferon Induced Protein With Tetratricopeptide Repeats 3 | −3.54 | 1E−40 | 3E−38 |
| AKR1C3  | Aldo-Keto Reductase Family 1 Member C3 | −3.35 | 2E−36 | 4E−34 |
| LINC00341 | Spectrin Repeat Containing Nuclear Envelope Family Member 3 | −3.31 | 1E−35 | 3E−33 |
| AKR1C2  | Aldo-Keto Reductase Family 1 Member C2 | −3.30 | 4E−65 | 6E−62 |
| PLEKIH4 | Pleckstrin Homology and RhoGEF Domain Containing G4 | −3.01 | 5E−47 | 2E−44 |
| PLEKHA6 | Pleckstrin Homology Domain Containing A6 | −2.96 | 1E−30 | 2E−28 |
| WNT2B   | Wnt Family Member 2B | −2.96 | 3E−56 | 3E−53 |
| PTX3    | Pentraxin 3 | −2.93 | 5E−29 | 7E−27 |
| DDX60   | DEXA/H-Box Helicase 60 | −2.80 | 5E−43 | 2E−40 |
| TOP2A   | DNA Toososerase II Alpha | −2.74 | 2E−35 | 4E−33 |
| SEMA3D  | Semaphorin 3D | −2.71 | 1E−28 | 1E−26 |
| CSF1    | Colony Stimulating Factor 1 | −2.70 | 5E−30 | 7E−28 |
| RAB27B  | RAB27B, Member RAS Oncogene Family | −2.69 | 7E−32 | 1E−29 |
| PARP10  | Poly(ADP-ribose) polymerase Family Member 10 | −2.62 | 2E−35 | 5E−33 |
| DUSP6   | Dual Specificity Phosphatase 6 | −2.49 | 3E−28 | 3E−26 |
| GMPR    | Guanosine Monophosphate Reductase | −2.47 | 8E−29 | 1E−26 |
| SMAD3   | Smad Family Member 3 | −2.46 | 2E−33 | 3E−31 |
| PHLD1A  | Pleckstrin Homology Like Domain Family A Member 1 | −2.42 | 2E−39 | 5E−37 |
| ISYNA1  | Inositol-3-Phosphate Synthase 1 | −2.31 | 6E−35 | 1E−32 |
| S1PR3   | Sphinosine-1-Phosphate Receptor 3 | −2.25 | 1E−42 | 4E−40 |
| ADM     | Adrenomedullin | −2.24 | 3E−37 | 6E−35 |
| PARP14  | Poly(ADP-ribose) polymerase Family Member 14 | −2.23 | 2E−28 | 3E−26 |
| UBE2L6  | Ubiquitin Conjugating Enzyme E2 L6 | −2.17 | 3E−41 | 8E−39 |
| ZFP36   | Zinc Finger Protein 36 | −2.13 | 1E−31 | 2E−29 |
| NAPB1   | Nucleic Acid Binding Protein 1 | −1.98 | 6E−38 | 1E−35 |
| TENC1   | Tensin Like C1 Domain Containing Phosphatase | −1.98 | 4E−30 | 5E−28 |
| ALDH3B1 | Aldehyde Dehydrogenase 3 Family Member B1 | −1.92 | 9E−34 | 2E−31 |
| CPA4    | Carboxypeptidase A4 | −1.83 | 3E−29 | 5E−27 |
| MOV10   | MOV10 RISC Complex RNA Helicase | −1.68 | 2E−29 | 3E−27 |

Table 2. Top 50 down-regulated genes.
Figure 2. Gene Ontology and canonical pathway analysis. (A) A table showing significant biological processes and canonical pathways from IPA for the differentially expressed genes found between donor control and TGFβ2 donor treated. (B) Gene Ontology (GO) analysis of the top 50 upregulated and downregulated genes investigating the cellular compartment, biological processes, and molecular functions of the top 50 upregulated and 50 downregulated genes analysed using the DAVID functional process on R. *p < 0.01, **p < 0.001, ***p < 0.0001.

Validation of differentially expressed genes by RT-qPCR. To validate the results obtained from the RNA-Seq analysis, candidate genes with expression changes induce by TGF-β2 and pre-determined to regulate processes involved in glaucoma development and pathogenesis, were analysed from the same donors using RT-qPCR (Fig. 4). Thirteen of the fifteen candidate genes demonstrated significant differential expression by RT-qPCR with EDN1 (p < 0.04), RASL11B (p < 0.04), NOX4 (p < 0.003), LEFTY2 (p < 0.003), CDKN2B (p < 0.03), ATP10A (p < 0.002), LDLRAD4 (p < 0.005), FNDC1 (p < 0.002), PMEPA1 (p < 0.02) and DACT1 (p < 0.002) showing statistical significance. With the exception of WNT2B, the differential expression of the genes validated by RT-qPCR correlate to the expression patterns shown in the RNA-Seq data set, therefore confirming the reliability of the RNA-seq data.

Discussion Understanding the TGF-β2 induced genome-wide transcriptome changes in the TM cells has provided insights into the pathophysiological mechanisms driving primary open angle glaucoma (POAG). To our knowledge, this is the first report to use RNA-seq analysis to investigate the human TM transcriptome profile following TGFβ2 treatment. Understanding the transcriptome is essential for interpreting the functional elements of the genome and revealing the molecular constituents of cells and tissues, and for understanding development and disease.33,34 Previous studies have performed gene expression studies using microarrays on cells derived from human glaucomatous donor eyes.26,27 These studies are challenging as glaucomatous donor eyes and surgical samples are limited, the individual donors can have received different medical treatments prior to sampling, small amounts of RNA are available from surgical samples and POAG development is multifactorial and variable between patients.28,35,36 Given the body of evidence implicating TGF-β2 in the development of POAG,9,12,19, we employed a TGFβ2-induced TM cell culture model to mimic the elevated TGF-β2 environment of POAG, therefore identifying differentially expressed genes and associated pathways that contribute to the pathogenesis of POAG in a hypothesis-independent and discovery-driven manner. Understanding the role of TGF-β2 in the outflow pathway is essential to develop new therapies based on the modulation of TGF-β2 signalling in the trabecular meshwork.31,32
GWAS in glaucoma have identified multiple novel disease-predisposing genes, but progress in uncovering the mechanisms by which these genes lead to glaucoma, a necessity to understanding disease pathogenesis and develop new therapies, has been considerably slower. The differentially expressed genes (DEGs) and altered pathways identified in this study can provide further insight into the pathophysiological impact of genetic variants associated with POAG. ATPase Phospholipid Transporting 10a (ATP10A) lies in a POAG mapped locus (GLC1I) on chr15q11-13 and is upregulated by steroid treatment in the TM. The association of genetic variants in CDKN2B with POAG has been replicated in multiple genome wide association studies. CDKN2B encodes a cyclin-dependent kinase inhibitor, p15INK4b, which plays an important role in the regulation of the cell cycle through the inhibition of cyclin-dependent kinase 4 (CDK4). The expression of CDKN2B is significantly induced by TGF-β and plays a role in the mediation of TGF-β-induced cell cycle arrest. TGF-β inhibits cell proliferation by producing G1 phase cell cycle arrest and CDKN2B, which forms a complex with either CDK4 or CDK6 preventing their activation, acts as an effector of TGF-β cell cycle arrest. CDKN2B was amongst the common TGF-β2 stimulated DEGs in the previous microarray studies and in this RNA-Seq dataset. The upregulation of CDKN2B and CDKN2B-AS1 in human TM cells is associated with senescence and interestingly there is a decline in the TM cell population with age and this decline is accelerated in POAG. The underlying mechanisms of TM cell loss with age and POAG have not been fully resolved and the interplay between TGF-β and TM senescence needs further investigation.

Unsurprisingly, several of the DEGs induced by TGF-β2 in the TM have been implicated in the regulation of TGF-β signalling. Follistatin-like 3 (FSTL3) is a member of the follistatin family which includes follistatin and both can inhibit the actions of activins and bone morphogenic proteins (BMPs). BMPs are members of the TGF-β superfamily which have been identified in the human TM and BMPs can block TGF-β2 induction of ECM proteins in the TM. The role of FSTL3 in glaucoma or following TGF-β2 induction in the TM is unknown, although FSTL3 has pro-fibrotic effects in cardiac fibroblasts, in partnership with connective tissue growth factor (CTGF). PMEPAI, LDLRAD4, SMAD7 and LEFTY2 are all negative regulators of TGF-β2.
Prostate transmembrane protein androgen induced 1 (PMEPA1) is a negative regulator of TGFβ signalling in prostate cancer cells\(^5^4\). Silencing SMAD7 in TM cells can attenuate the expression of ECM components induced by TGF-β\(^2^5^7\). Left–right determination factor 2 (LEFTY2) was significantly upregulated in the TGF-β\(^2\) stimulated TM cells and negatively modulates both TGFβ and BMP signalling through the inhibition of R-Smad protein phosphorylation\(^5^6\). CTGF expression is induced by TGFβ, and while FSTL3 interacts with CTGF to drive fibrosis, LEFTY2 plays a significant role in the regulation of the ECM and the inhibition of the pro-fibrotic effects of CTGF\(^5^8,5^9\). CTGF is an important regulator and enhancer of TGF-β signalling in fibrosis which has been implicated in the pathogenesis of POAG\(^5^9,6^0\).

TM contractility is induced by endothelin 1 (EDN1), a potent vasoactive peptide, which has been linked to glaucoma pathogenesis in both humans and animal models\(^6^1,6^2\). Elevated expression of EDN1 in response to TGF-β\(^2\) was identified in this study and elevated EDN1 gene and protein expression has previously been shown in cultured trabecular meshwork cells treated with both TGF-β\(^1\) and -β\(^2^6^5\). EDN1 has variable effects on IOP in animal model\(^6^3\) but \textit{in-vitro} studies in bovine and human TM cells show that there is increased TM cell contractility in response to elevated EDN1 expression EDN\(^1^4^4,5^7\); and this contractility can be reversed with Rho kinase inhibitors\(^6^6\). In podocytes TGF-β induces the synthesis and release of EDN1 which initiates mitochondrial ROS, mitochondrial DNA damage and mitochondrial dysfunction\(^6^8\). Similarly, there is an interplay between ROS and TGF-β in glaucoma\(^6^9\), and NOX4 is one of the major sources of cellular oxidative stress and is an important downstream effector in mediating TGF-β-induced fibrosis in the heart, lungs and kidneys via the production of ROS\(^7^0\). NOX4 was significantly upregulated by TGF-β\(^2\) in our study and has been demonstrated to drive ECM production, actin stress fibre formation and αSMA expression in the TM\(^7^1\).

Alongside the TGF-β signalling, the RhoA signalling pathway was also highlighted in both the GO and IPA pathway analysis as it had a many differentially expressed genes common to our data set and the regulatory pathway. The Rho pathway has pleiotropic functions including the regulation of cellular contraction, motility, morphology, polarity, cell division, apoptosis and gene expression\(^7^2\). In the anterior eye the Rho signalling pathway in combination with its major downstream effector, Rho-associated protein kinase (ROCK), modulate the cytoskeletal integrity of cells, synthesis of ECM components, and the permeability of cells in both the Schlemm's canal and TM\(^7^2,7^3\). Several studies have highlighted the potential of ROCK inhibitors to reverse the physiological effects induced by TGF-β\(^2\), including reducing cell stiffness and HTM contractability\(^7^4,7^5\). Important therapeutic advances have thus been made with the ROCK inhibitor Ripasudil® approved for clinical use in glaucoma patients in Japan from 2014\(^7^6,7^7\). Following that, Rhopressa® was approved by the FDA in the USA in December 2017 for lowering the IOP in POAG patients\(^7^8\). Therapeutic agents targeting other TGF-β\(^2\) activated pathways in the TM highlighted in this RNA-seq dataset are worthy of further investigation. The nuclear factor

---

**Figure 4.** RT-qPCR confirmation and comparison of RNA-Seq results. A total of 5 control and TGFβ\(^2\) stimulated TM donor cells were used for the validation of gene expression patterns from the RNASeq analysis using RT-qPCR. Values were normalised to GAPDH and graphed as log fold change. Statistical significance was determined using a two-sample t test (*p* < 0.0005).
(erythroid-derived 2)-like 2 (Nrf2), PI3K-Akt, MAPK and HIPPO signalling pathways have been implicated in POAG and TM patho-physiology, and were enriched in the pathway analysis supporting further study and therapeutic manipulation in glaucoma. In conclusion, this study presents a comprehensive characterisation of differentially expressed genes in response to TGF-β2 in the human trabecular meshwork and a mechanistic insight into the underlying biology of this disease. The trabecular meshwork plays a significant role in the regulation of outflow facility and intraocular pressure. Raised intra-ocular pressure is a major risk factor for primary open angle glaucoma, and the identification and characterisation of TGF-β2 dependent differentially expressed genes and pathways in human HTM cells is essential to understand the patho-physiology of glaucoma and to develop new therapeutic agents.

Received: 4 October 2021; Accepted: 13 May 2022
Published online: 10 June 2022

References
1. Jonas, J. B. et al. Glaucoma. The Lancet 390(10108), 2183–2193 (2017).
2. Bourne, R. et al. Trends in prevalence of blindness and distance and near vision impairment over 30 years: An analysis for the Global Burden of Disease Study. Lancet Glob. Health 9(2), e130–e143 (2021).
3. Alqawlaq, S., Flanagan, J. G. & Sivak, J. M. All roads lead to glaucoma: Induced retinal injury cascades contribute to a common neurodegenerative outcome. Exp. Eye Res. 183, 88–97 (2019).
4. Sommer, A. et al. Relationship Between Intraocular Pressure and Primary Open Angle Glaucoma Among White and Black Americans: The Baltimore Eye Study. Arch. Ophthalmol. 109(8), 1090–1095 (1991).
5. Wormald, R., Virgili, G. & Azuara-Blanco, A. Systematic reviews and randomised controlled trials on open angle glaucoma. Eye 34(1), 161–167 (2020).
6. Braunger, B. M., Fuchshofer, R. & Tamm, E. R. The aqueous humor outflow pathways in glaucoma: A unifying concept of disease mechanisms and causative treatment. Eur. J. Pharm. Biopharm. 95, 173–181 (2015).
7. Gharihkhani, P. et al. Genome-wide meta-analysis identifies 127 open-angle glaucoma loci with consistent effect across ancestries. Nat. Commun. 12(1), 1258 (2021).
8. Danford, J. D. et al. Characterising the “POAGome”: A bioinformatics-driven approach to primary open-angle glaucoma. Prog. Retina. Eye Res. 58, 89–114 (2017).
9. Prendes, M. A., Harris, A., Wirostko, B. M., Gerber, A. L. & Siesky, B. The role of transforming growth factor β in glaucoma and the therapeutic implications. Br. J. Ophthalmol. 97(6), 680–686 (2013).
10. Inatani, M. et al. Transforming growth factor-beta 2 levels in aqueous humor of glaucomatous eyes. Graefes Arch. Clin. Exp. Ophthalmol. 239(2), 109–113 (2001).
11. Tripathi, R. C., Li, J., Chan, W. F. & Tripathi, B. J. Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta2. Exp. Eye Res. 59(6), 723–727 (1994).
12. Wordinger, R. J., Sharma, T. & Clark, A. F. The role of TGF-β2 and bone morphogenetic proteins in the trabecular meshwork and glaucoma. J. Ocular Pharmacol. Ther. 30(2–3), 154–162 (2014).
13. Jampel, H. D., Roche, N., Stark, W. J. & Roberts, A. B. Transforming growth factor-β in human aqueous humor. Curr. Eye Res. 9(10), 963–969 (1990).
14. Tovar-Vidades, T., Clark, A. F. & Wordinger, R. J. Transforming growth factor-beta2 utilizes the canonical Smad-signaling pathway to regulate tissue transglutaminase expression in human trabecular meshwork cells. Exp. Eye Res. 93(4), 442–451 (2011).
15. Shepard, A. R. et al. Adenoviral gene transfer of active human transforming growth factor-beta2 elevates intraocular pressure and reduces outflow facility in rodent eyes. Invest. Ophthalmol. Vis. Sci. 51(4), 2067–2076 (2010).
16. Fleenor, D. L. et al. TGFβ2-induced changes in human trabecular meshwork: Implications for intraocular pressure. Invest. Ophthalmol. Vis. Sci. 47(1), 226–234 (2006).
17. Rohen, J. W., Lütjen-Drecoll, E., Flügel, C., Meyer, M. & Grieser, I. Ultrastructure of the trabecular meshwork in untreated cases of primary open-angle glaucoma (POAG). Exp. Eye Res. 56(6), 683–692 (1993).
18. Gottanka, J., Johnson, D. H., Martus, P. & Lütjen-Drecoll, E. Severity of optic nerve damage in eyes with POAG is correlated with changes in the trabecular meshwork. J. Glaucoma 6(2), 123–132 (1997).
19. Fuchshofer, R. & Tamm, E. R. The role of TGFβ in the pathogenesis of primary open-angle glaucoma. Cell Tissue Res. 347(1), 279–290 (2012).
20. David, C. J. & Massagué, J. Contextual determinants of TGFβ action in development, immunity and cancer. Nat. Rev. Mol. Cell Biol. 19(7), 419–435 (2018).
21. Siegel, P. M. & Massagué, J. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat. Rev. Cancer 11(1), 807–820 (2003).
22. Wang, J. et al. Targeting transforming growth factor-β signaling in primary open-angle glaucoma. J. Glaucoma 26(4), 390–395 (2017).
23. Fuchshofer, R., Stephan, D. A., Russell, P. & Tamm, E. R. Gene expression profiling of TGF-β2- and/or BMP7-treated trabecular meshwork cells: Identification of Smad7 as a critical inhibitor of TGF-β2 signaling. Gene Exp. 86(6), 1020–1032 (2011).
24. Zhao, X., Ramsey, K. E., Stephan, D. A. & Russell, P. Gene and protein expression changes in human trabecular meshwork cells treated with transforming growth factor-beta. Invest. Ophthalmol. Vis. Sci. 45(11), 4023–4034 (2004).
25. Flügel-Koch, C., Ohlmann, A., Fuchshofer, R., Welge-Lüssen, U. & Tamm, E. R. Thombospondin-1 in the trabecular meshwork: Localization in normal and glaucomatous eyes, and induction by TGF-β1 and dexamethasone in vitro. Exp. Eye Res. 79(5), 649–663 (2004).
26. Medina-Ortiz, W. E., Belmares, R., Neubauer, S., Wordinger, R. J. & Clark, A. F. Cellular fibronectin expression in human trabecular meshwork and induction by transforming growth factor-β2. Invest. Ophthalmol. Vis. Sci. 54(10), 6779–6788 (2013).
27. Zhao, S., Fung-Leung, W.-P., Bittner, A., Ngo, K. & Liu, X. Comparison of RNA-Seq and microarray in transcriptome profiling of activated T cells. PLoS ONE 9(1), e78644 (2014).
28. Liu, Y. et al. Gene expression profile in human trabecular meshwork from patients with primary open-angle glaucoma. Invest. Ophthalmol. Vis. Sci. 54(9), 6382–6389 (2013).
29. Keller, K. E. et al. Consensus recommendations for trabecular meshwork cell isolation, characterization and culture. Exp. Eye Res. 171, 164–173 (2018).
30. Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nat. Protoc. 4(1), 44–57 (2009).
31. Huang, D. W., Sherman, B. T. & Lempicki, R. A. Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37(1), 1–13 (2009).
32. Shannon, P. et al. Cytoscape: A software environment for integrated models of biomolecular interaction network. *Genome Res.* **13**(11), 2498–2504 (2003).

33. Hawkins, R. D., Hon, G. C. & Ren, B. Next-generation genomics: An integrative approach. *Nat. Rev. Genet.* **11**(7), 476–486 (2010).

34. Wang, Z., Gerstein, M. & Snyder, M. RNA-Seq: A revolutionary tool for transcriptomics. *Nat. Rev. Genet.* **10**(1), 57–63 (2009).

35. Cai, J. et al. Expression profiling of human Schlemm's canal endothelial cells from eyes with and without glaucoma. *Invest. Ophthal. Mol. Vis.* **36**(11), 6477–6573 (2015).

36. Iglesias, A. J. et al. Genes, pathways, and animal models in primary open-angle glaucoma. *Eye (Basingstoke)* **29**(10), 1285–1298 (2015).

37. Craig, I. E. et al. Multitrait analysis of glaucoma identifies new risk loci and enables polygenic prediction of disease susceptibility and progression. *Nat. Genet.* **52**(2), 160–166 (2020).

38. Tam, V. et al. Benefits and limitations of genome-wide association studies. *Nat. Rev. Genet.* **20**(8), 467–484 (2019).

39. Wiggins, J. L. & Pasquali, L. R. Genetics of glaucoma. *Hum. Mol. Genet.* **26**, R1–R27 (2017).

40. Allingham, R. R. et al. Expression profiling of human trabecular meshwork cells induced by triamcinolone and dexamethasone. *Invest. Ophthalmol. Vis. Sci.* **49**(5), 1886–1897 (2008).

41. Hannon, G. J. & Beach, D. P53NKB4 is a potential effector of TGF-β-induced cell cycle arrest. *Nature* **371**(6494), 257–261 (1994).

42. Nanda, V. et al. CDK2NB2 regulates TGF-β signaling and smooth muscle cell investment of hypoxic neovessels. *Circ. Res.* **118**(2), 230–240 (2016).

43. Rathé, S. et al. Molecular genetics and functional analysis implicate CDK2NB2A-CDK2NB2 involvement in POAG pathogenesis. *Cells* **9**(9), 1934 (2020).

44. Ravit, M. & Wenner, C. E. Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-β. *Adv. Cancer Res.* **71**, 165–207 (1997).

45. Fleerom, D. L. et al. TGFbeta2-induced changes in human trabecular meshwork: Implications for intraocular pressure. *Invest. Ophthalmol. Vis. Sci.* **47**(1), 226–234 (2005).

46. Alvarado, J., Murphy, C. & Juster, R. Trabecular meshwork cellularity in primary open-angle glaucoma and nonglaucomatous normals. *Ophthalmology* **91**(6), 564–579 (1984).

47. Grierson, I. & Howes, R. C. Age-related depletion of the cell population in the human trabecular meshwork. *Eye* **1**(2), 204–210 (1987).

48. Bollinger, K. E. et al. Quantitative proteomics: TGFβ2 signaling in trabecular meshwork cells. *Invest. Ophthalmol. Vis. Sci.* **52**(11), 8287–8294 (2011).

49. Yu, A. L., Birke, K., Moriniere, J. & Welge-Lüssen, U. TGF-β2 induces senescence-associated changes in human trabecular meshwork cells. *Invest. Ophthalmol. Vis. Sci.* **51**(11), 5718–5723 (2010).

50. Xia, Y. & Schneyer, A. L. The biology of activin: Recent advances in structure, regulation and function. *J. Endocrinol.* **202**(1), 1–12 (2009).

51. Fuchsroher, R., Yu, A. H. L., Welge-Lüssen, U. & Tamm, E. R. Bone morphogenetic protein-7 is an antagonist of transforming growth factor-β in human trabecular meshwork cells. *Invest. Ophthalmol. Vis. Sci.* **48**(2), 715–726 (2007).

52. Parise, K. D. et al. Follistatin-like 3 mediates paracrine fibroblast activation by cardiomyocytes. *J. Cardiovasc. Transl. Res.* **5**(6), 814–826 (2012).

53. Blei, A. M. & Huang, H. P. MPEPA1 guards against TGF-β-mediated prostate cancer bone metastasis. *Asian J. Urol.* **3**(1), 1–3 (2016).

54. Su, Y. et al. Smad7 siRNA inhibit expression of extracellular matrix in trabecular meshwork cells treated with TGF-β2. *Mol. Vis.* **18**, 1881–1884 (2012).

55. Ulloa, L. & Tabshizad, S. Lefty inhibits receptor-regulated smad phosphorylation induced by the activated transforming growth factor-β receptor. *J. Biol. Chem.* **276**(24), 21397–21404 (2001).

56. Su, Y. et al. Smad7 siRNA inhibit expression of extracellular matrix in trabecular meshwork cells. *Mol. Vis.* **18**, 1881 (2012).

57. Mason, J. K. et al. Lefty contributes to the remodeling of extracellular matrix by inhibition of connective tissue growth factor and collagen mRNA expression and increased proteolytic activity in a fibrosarcoma model. *J. Biol. Chem.* **277**(1), 407–415 (2002).

58. Jungprasert, et al. Connective tissue growth factor causes glaucoma by modifying the actin cytoskeleton of the trabecular meshwork. *Am. J. Pathol.* **180**(6), 2386–2403 (2012).

59. Wallace, D. M., Murphy-Ullrich, J. E., Downs, J. C. & O'Brien, C. J. The role of matricellular proteins in glaucoma. *Exp. Eye Res.* **102**, 251–263 (2011).

60. Chen, H. Y. et al. Endothelin antagonism as an active principle for glaucoma therapy. *Br. J. Pharmacol.* **162**(4), 806–816 (2011).

61. Yorio, T., Krishnamoorthy, R. & Prassana, G. Endothelin: Is it a contributor to glaucoma pathophysiology? *J. Glaucoma* **11**(3), 259–270 (2002).

62. Zhou, E. H. et al. A compact whole-eye perfusion system to evaluate pharmacologic responses of outflow facility. *Invest. Ophthalmol. Vis. Sci.* **58**(7), 2991–3003 (2017).

63. Cellini, M., Versura, P., Trérè, D. & Campos, E. C. Effects of endothelin-1 on human trabecular meshwork cell contraction: An in vitro cell culture model. *Ophthalmic Res.* **37**(1), 43–49 (2005).

64. Renieri, G. et al. Effects of endothelin-1 on calcium-independent contraction of bovine trabecular meshwork. *Graefes Arch. Clin. Exp. Ophthalmol.* **246**(8), 1107–1115 (2008).

65. Rosenblad, R. et al. Effects of ML-7 and Y-27632 on carbachol- and endothelin-1-induced contraction of bovine trabecular meshwork. *Exp. Eye Res.* **80**(6), 837–845 (2005).

66. Wiederholt, M., Bielka, S., Schweig, F., Lütjen-Drecoll, E. & Lepple-Wienhues, A. Regulation of outflow rate and resistance in the perfused anterior segment of the bovine eye. *Exp. Eye Res.* **61**(2), 223–234 (1995).

67. Daehn, I. et al. Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis. *J. Clin. Investig.* **124**(4), 1608–1621 (2014).

68. Chen, H. Y. et al. Characterization of tgf-β by induced oxidative stress in human trabecular meshwork cells. *Antioxidants* **10**(1), 1–31 (2021).

69. Jiang, F., Liu, G.-S., Dasting, G. J. & Chan, E. C. NADPH oxidase-dependent redox signaling in TGF-β-mediated fibrotic responses. *Redox Biol.* **2**, 267–272 (2014).

70. Rao, V. R. & Stubs, E. B. TGF-β modulates oxidative stress in human trabecular meshwork cells by selectively enhancing NADPH oxidase 4 expression. *Investig. Ophthalmol. Vis. Sci.* **62**(4), 4 (2021).

71. Rao, P. V., Pattabiraman, P. P. & Kopczynski, C. Role of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: Bench to bedside research. *Exp. Eye Res.* **158**, 23–32 (2017).

72. Wang, J., Liu, X. & Zhong, Y. Rho/Rho-associate kinase pathway in glaucoma. *Int. J. Onkol.* **43**, 1357–1367 (2013).

73. Watanabe, M. et al. Diverse effects of pan-ROCK and ROCK2 inhibitors on 2 D and 3 D cultured human trabecular meshwork (HTM) cells treated with TGFβ2. *Sci. Rep.* **11**, 15286 (2021).

74. Ghanem, A. A., Mokbel, T., Ghanem, A. A. & Elnozahry, A. Rho-kinase inhibitors as a novel medication for glaucoma treatment: A review of the literature. *Egypt. J. Ophthalmol.* **1**(2), 110–20 (2021).

75. Garnock-Jones, K. P. Ripsudil: First global approval. *Drugs* **74**, 2211–2215 (2014).
77. Tanihara, H. et al. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension. *Acta Ophthalmol.* **94**, e26–e34 (2016).
78. Sturdivant, J. M. et al. Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma. *Bioorg. Med. Chem. Lett.* **26**, 2475–2480 (2016).
79. Pervan, C. L. Smad-independent TGF-β2 signaling pathways in human trabecular meshwork cells. *Exp. Eye Res.* **158**, 137–145 (2017).
80. Wang, X. et al. Mutual regulation of the Hippo/Wnt/LPA/TGF-β signaling pathways and their roles in glaucoma (Review). *Int. J. Mol. Med.* **41**(3), 1201–1212 (2018).
81. Yan, J. et al. Integrative transcriptomic and proteomic analysis reveals CD9/ITGA4/PI3K-Akt axis mediates trabecular meshwork cell apoptosis in human glaucoma. *J. Cell. Mol. Med.* **24**(1), 814–829 (2020).
82. Wang, M., Li, J. & Zheng, Y. The potential role of nuclear factor erythroid 2-related factor 2 (Nrf2) in glaucoma: A review. *Med. Sci. Monit.* **17**, 26 e921514 (2020).

**Author contributions**
B.C. and K.L.: equal contribution, implementation of the research, analysis of the results and preparation of the figures. B.C. and C.E.W. wrote the main manuscript. B.L. completed the bioinformatic analysis. X.F. analysed data and prepared figures. D.A.S., C.S., K.W. and C.E.W. contributed to funding acquisition and study design and supervision. All authors reviewed the manuscript.

**Funding**
Glaucoma UK, Fight for Sight (UK), Mason Medical Research Foundation, UK and Eire Glaucoma Society.

**Competing interests**
The authors declare no competing interests.

**Additional information**
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-13573-8.

Correspondence and requests for materials should be addressed to C.E.W.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022